Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Januar 2019 07:00 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors

WATERTOWN, Mass., Jan. 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
03. Januar 2019 07:00 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Provides 2019 Commercial Update

- DEXYCUTM commercial launch now expected in 1Q19, earlier than prior guidance of 1H19 - - YUTIQTM commercial launch on track for 1Q19 - WATERTOWN, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) --...
17. Dezember 2018 16:23 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index

WATERTOWN, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic...
27. November 2018 16:05 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary

- Industry veteran who brings over 25 years of legal expertise in the medical device industry to newly created position - WATERTOWN, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- EyePoint...
12. November 2018 07:00 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)

WATERTOWN, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
06. November 2018 16:10 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

WATERTOWN, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
06. November 2018 06:00 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments

-YUTIQ™ approved by U.S. FDA; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year micro-insert product using...
05. November 2018 16:11 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region

WATERTOWN, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
30. Oktober 2018 07:30 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
30. Oktober 2018 07:00 ET | Quelle: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors

- Seasoned Pharmaceutical R&D and Operations Leader with over 30 Years of Experience - WATERTOWN, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a...

Vorherige Seite